Mraz Amerine & Associates Inc. Has $349,000 Stake in Merck & Company, Inc. (MRK)

Mraz Amerine & Associates Inc. Has $349,000 Stake in Merck & Company, Inc. (MRK)

Mraz Amerine & Associates Inc. raised its position in Merck & Company, Inc. (NYSE:MRK) by 0.1% during the third quarter, according to its most recent Form 13F filing with the SEC. The firm owned 5,589 shares of the company’s stock after buying an additional 5 shares during the period. Mraz Amerine & Associates Inc.’s holdings in Merck & Company were worth $349,000 at the end of the most recent reporting period.

A number of other hedge funds and other institutional investors have also made changes to their positions in MRK. Solaris Asset Management LLC boosted its position in shares of Merck & Company by 3.8% in the third quarter. Solaris Asset Management LLC now owns 1,635 shares of the company’s stock worth $102,000 after buying an additional 60 shares in the last quarter. Acrospire Investment Management LLC boosted its position in shares of Merck & Company by 5.9% in the second quarter. Acrospire Investment Management LLC now owns 1,800 shares of the company’s stock worth $104,000 after buying an additional 100 shares in the last quarter. Roble Belko & Company Inc boosted its position in shares of Merck & Company by 124.7% in the second quarter. Roble Belko & Company Inc now owns 1,802 shares of the company’s stock worth $104,000 after buying an additional 1,000 shares in the last quarter. NewSquare Capital LLC boosted its position in shares of Merck & Company by 14.2% in the second quarter. NewSquare Capital LLC now owns 2,104 shares of the company’s stock worth $121,000 after buying an additional 261 shares in the last quarter. Finally, Pinkerton Retirement Specialists LLC boosted its position in shares of Merck & Company by 1,925.2% in the second quarter. Pinkerton Retirement Specialists LLC now owns 2,248 shares of the company’s stock worth $130,000 after buying an additional 2,137 shares in the last quarter. Hedge funds and other institutional investors own 73.63% of the company’s stock.

Shares of Merck & Company, Inc. (NYSE:MRK) opened at 61.75 on Friday. The company has a market capitalization of $170.25 billion, a PE ratio of 31.54 and a beta of 0.77. Merck & Company, Inc. has a 52-week low of $47.97 and a 52-week high of $65.46. The company has a 50-day moving average of $60.88 and a 200 day moving average of $61.40.

The firm also recently declared a quarterly dividend, which was paid on Monday, January 9th. Shareholders of record on Thursday, December 15th were given a $0.47 dividend. This is a boost from Merck & Company’s previous quarterly dividend of $0.46. This represents a $1.88 annualized dividend and a yield of 3.04%. The ex-dividend date was Tuesday, December 13th. Merck & Company’s dividend payout ratio is 95.92%.

Several analysts have recently weighed in on MRK shares. Vetr lowered shares of Merck & Company from a “hold” rating to a “sell” rating and set a $57.17 price objective for the company. in a report on Wednesday, December 14th. Piper Jaffray Companies raised shares of Merck & Company from a “neutral” rating to an “overweight” rating and set a $72.00 price objective for the company in a report on Thursday, January 12th. Guggenheim raised shares of Merck & Company from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $61.63 to $70.00 in a report on Thursday, January 12th. Zacks Investment Research raised shares of Merck & Company from a “hold” rating to a “buy” rating and set a $67.00 price objective for the company in a report on Tuesday, December 6th. Finally, Bank of America Corporation raised shares of Merck & Company from a “neutral” rating to a “buy” rating and raised their price objective for the stock from $57.00 to $70.00 in a report on Thursday, October 13th. One equities research analyst has rated the stock with a sell rating, nine have issued a hold rating and thirteen have issued a buy rating to the stock. The company has an average rating of “Buy” and a consensus target price of $66.31.

In other Merck & Company news, Director Rochelle B. Lazarus sold 20,000 shares of the company’s stock in a transaction that occurred on Wednesday, November 2nd. The shares were sold at an average price of $59.06, for a total value of $1,181,200.00. Following the completion of the transaction, the director now directly owns 9,594 shares in the company, valued at approximately $566,621.64. The sale was disclosed in a filing with the SEC, which is available at this hyperlink. Also, EVP Julie L. Gerberding sold 85,523 shares of the company’s stock in a transaction that occurred on Monday, November 7th. The shares were sold at an average price of $60.02, for a total transaction of $5,133,090.46. Following the completion of the transaction, the executive vice president now owns 77,762 shares of the company’s stock, valued at $4,667,275.24. The disclosure for this sale can be found here. Over the last 90 days, insiders sold 245,523 shares of company stock valued at $15,418,490. Corporate insiders own 0.05% of the company’s stock.

About Merck & Company

Merck & Co, Inc is a global healthcare company. The Company offers health solutions through its prescription medicines, vaccines, biologic therapies and animal health products, which it markets directly and through its joint ventures. It operates through one segment, Pharmaceutical. The Company’s Pharmaceutical segment includes human health pharmaceutical and vaccine products marketed either directly by the Company or through joint ventures.

Want to see what other hedge funds are holding MRK? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Merck & Company, Inc. (NYSE:MRK).

Related posts

Leave a Comment